Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 2

1(20.0%)

5Total

N/A(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06229665Phase 2Active Not Recruiting

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)

Role: lead

NCT06351605Recruiting

A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (EUROLIGHT) (EUROLIGHT)

Role: lead

NCT03878420Not ApplicableCompleted

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE II)

Role: lead

NCT04522999Not ApplicableCompleted

Study of Photobiomodulation Effect on Electroretinogram Outcomes in Dry Age-Related Macular Degeneration

Role: lead

NCT02725762Not ApplicableCompleted

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration

Role: lead

NCT04065490Not ApplicableActive Not Recruiting

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)

Role: lead

All 6 trials loaded